Takeda India exec views rare disease management

The Indian pharma market is increasing at an annual growth rate of 15%, twice the world market growth rate, and has become one of the most expansive sectors in India. While the pharma industry is expected to grow to $130 billion by 2030, there are deep seated challenges posed at this industry when it comes to rare disease management.

There are more than 7,000 defined genetic rare diseases out of which about 450 are treatable. In India, rare diseases pose a significant challenge to public health systems in terms of difficulty in collecting epidemiological data. This poses a threat on difficulty in research and development, making a correct and timely diagnosis challenging, but it also opens up a landscape of opportunities in this area.

Commenting on the situation, Serina Fischer, general manager of Japanese pharma giant Takeda’s (TYO: 4502) Indian business unit, said: “As we look to 2023, we are optimistic that more advances can be made in the fight against rare diseases. Through the tireless work of researchers, clinicians, and patient advocates, we are seeing a greater understanding of rare diseases, their diagnoses, and potential treatments. At Takeda, we have been committed to increasing awareness and diagnosis of rare diseases and introducing innovative treatment in the areas of unmet needs.”